Premium
The effect of sertindole on QTD and TPTE
Author(s) -
Nielsen J.,
Andersen M. P.,
Graff C.,
Kanters J. K.,
Hardahl T.,
Dybbro J.,
Struijk J. J.,
Meyer J. M.,
Toft E.
Publication year - 2010
Publication title -
acta psychiatrica scandinavica
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.849
H-Index - 146
eISSN - 1600-0447
pISSN - 0001-690X
DOI - 10.1111/j.1600-0447.2009.01534.x
Subject(s) - sertindole , qt interval , medicine , cardiology , anesthesia , haloperidol , dopamine
Nielsen J, Andersen MP, Graff C, Kanters JK, Hardahl T, Dybbro J, Struijk JJ, Meyer JM, Toft E. The effect of sertindole on QTD and TPTE. Objective: Recent research suggests that other surrogate markers than QTc, including QTc dispersion and Tpeak‐Tend, may better correlate with cardiac arrhythmia risk. While sertindole significantly prolongs the QTc interval, the effects on other markers of arrhythmia risk, such as QTc dispersion and Tpeak‐Tend are unknown. Method: Digital 12‐lead ECG was recorded at baseline and at steady‐state in 37 patients switched to sertindole. ECG was analysed for Fridericia‐corrected QT duration (QTcF), QT dispersion and Tpeak‐Tend. Results: From a baseline QTcF of 407 ± 22 ms, mean QTcF prolongation during sertindole treatment was 20 ± 23 ms, P < 0.01. No effect on QTc dispersion was found (−1 ± 11 ms; P = 0.41). No increased duration of the Tpeak‐Tend interval from baseline was found (+7 ± 21 ms; P = 0.05). Conclusion: These findings might be related to the absence of confirmed Torsade de Pointes (TdP) cases related to sertindole exposure, despite sertindole’s QTc prolonging effects.